NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report second quarter financial results on or before August 14, 2018 and host a conference call on Wednesday, August 22, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss second quarter 2018 financial results.

To access the conference call, U.S.-based listeners should dial (888) 803-5993 and international listeners should dial (706) 634-5454. All listeners should provide the operator with the following passcode: 8188784. Individuals interested in listening to the live conference call via the internet may do so by visiting the Company’s website at

Following the conclusion of the conference call, a replay will be available through August 28, 2018 and can be accessed by dialing (855) 859-2056 from within the U.S., or (404) 537-3406 from outside the U.S. To access the replay, all listeners should provide the following passcode: 8188784. The webcast will be available for a period of time on the Company’s website at

About PAVmed

PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its three lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoCheck), infusions (PortIO and NextFlo and pediatric ear infections (DisappEAR). The company is also developing innovative products in other areas while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit


Contact Data